Oral ethinylestradiol in castration resistent prostate cancer: 10 year experience by Sciarra, Alessandro et al.
JOBNAME: No Job Name PAGE: 1 SESS: 15 OUTPUT: Thu Aug 28 09:20:00 2014 SUM: EF2700DF
/Xpp84/wiley_journal_I/IJU/iju_v0_i0/iju_12613
Original Article
Oral ethinylestradiol in castration-resistant prostate cancer:
A 10-year experience
Alessandro Sciarra, Vincenzo Gentile, Susanna Cattarino, Alessandro Gentilucci, Andrea Alfarone,
Giuseppe D’Eramo and Stefano Salciccia
Department of Urology, University Sapienza, Rome, Italy
Abbreviations & Acronyms
CI = confidence interval
CRPC = castration-resistant
prostate cancer
DES = diestylstilbestrol
EAU = European
Urological Association
ECOG = European
Cooperative Oncology
Group
HR = hazard ratio
LHRH = luteinizing
hormone releasing
hormone
mCRPC = metastatic
castration-resistant prostate
cancer
PC = prostate cancer
PSA = prostate-specific
antigen
Correspondence: Alessandro
Sciarra ••, Department of
Urology, University Sapienza
and Policlinico Umberto I, Viale
Policlinico, 00161 Rome, Italy.
Email: sciarra.md@libero.it
Received 21 March 2014;
accepted 8 August 2014.
Objectives: To describe our 10-year experience with the use of oral ethinylestradiol in the
treatment of metastatic castration-resistant prostate cancer.
Methods: From February 2000 to April 2010, 116 patients with a metastatic castration-
resistant prostate cancer were prospectively submitted to oral ethinylestradiol monotherapy.
Inclusion criteria were: diagnosis of castration-resistant prostate cancer after failure of at
least two lines of androgen deprivation therapy and radiological evidence of metastases.
Exclusion criteria were: symptomatic cases with a European Cooperative Oncology Group
score >2 and severe or uncontrolled cardiovascular diseases. At inclusion in the study, all
patients discontinued the previous androgen deprivation therapy and started oral
ethinylestradiol at the daily dose of 1 mg. Aspirin (100 mg/daily) was concomitantly given.
Results: The median ethinylestradiol therapy duration was 15.9 months (range 8–36
months), whereas the median follow up of patients was 28 months (range 13–36 months).
During ethinylestradiol therapy, a confirmed prostate-specific antigen response was found
in 79 patients (70.5%). The median time to prostate-specific antigen progression was
15.10 months (95% confidence interval 13.24–18.76 months). A toxicity requiring treatment
cessation was observed in 26 patients (23.2%) at a median time of 16 months (mainly
thromboembolism).
Conclusions: Our 10-year experience shows that ethinylestradiol provides a prostate-
specific antigen response in a high percentage of patients with metastatic castration-
resistant prostate cancer. Cardiovascular toxicity can be managed through accurate patient
selection, close follow up and a concomitant anticoagulation therapy.
Key words: advanced disease, castration resistant, estrogens, hormone therapy, pros-
tate neoplasm.
Introduction
First-line medical treatment for advanced PC is represented by androgen withdrawal, mainly by
the use of a LHRH agonist with or without the combination of an anti-androgen. High initial
response rates are expected, but progression to a CRPC is inevitable after a variable follow up.
Treatment options for CRPC mainly include palliative chemotherapy, such as docetaxel or
cabazitaxel, but also adrenolytic agents, estrogenic compounds or other anti-androgenic
manipulations.1–3
Recently, there has been a renewed interest in using estrogens as medical therapy for PC and
CRPC, as also described by the EAU guidelines.1 In contrast, it is also true that the development
of new significant treatment strategies for CRPC might limit the use of an old therapy, such
estrogens. The interest in estrogens, in particular for CRPC cases, is based on: (i) estrogens
represent a different way of achieving castration, and it is possible that the beneficial effect of
estrogens is also based on a direct cytotoxic effect on PC cells;4,5 (ii) discovery of new estrogen
receptors in PC tissue that can be upregulated by first-line castration therapies;6 and (iii) clinical
trials, in particular using DES, showing a high rate of PSA response in CRPC.7
The aim of the present study was to describe our 10-year experience with the use of oral
ethinylestradiol in the treatment of mCRPC cases.
Methods
This was a single center prospective analysis. From February 2000 to April 2010, 116 patients
with a mCRPC were detected and prospectively submitted to oral ethinylestradiol monotherapy
at our department.
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Patient selection
Inclusion criteria were: diagnosis of CRPC after failure of at
least two lines of androgen deprivation therapy and radiological
evidence of metastases. Exclusion criteria were: symptomatic
cases with an ECOG score >2 (these cases were selected for
immediate chemotherapy), severe or uncontrolled cardiovascu-
lar diseases (defined as NewYork Heart Association class III, or
congestive heart failure, myocardial infarction within 6 months,
unstable angina, deep venous thrombosis pulmonary embo-
lism) and concomitant presence of other advanced malignan-
cies or a life expectancy less than 3 months.8 All patients had
mCRPC defined as progressive disease (PSA rising and/or evi-
dence of progression at imaging) despite castration testosterone
levels (<50 ng/dL or <1.7 nmol/L).1 Previous androgen depri-
vation therapies were: LHRH agonist monotherapy, at failure
combination with a pure anti-androgen; and combination
therapy with LHRH agonist and pure anti-androgen, at failure
anti-androgen withdrawal for at least 6 weeks. Baseline data
included age, previous local therapies (surgery or radiation
therapy), type and duration of previous hormone therapies,
ECOG score, PSA levels, hematological and biochemical vari-
ables, and number and site of metastases (defined at bone scan,
magnetic resonance imaging or computer tomography scan).
Ethinylestradiol treatment
All 116 CRPC patients were treated as part of our clinical
practice, on an outpatient basis following the Declaration of
Helsinki principles, and all gave informed consent for treatment
(informed on the possible different options and on the possible
side-effects). The clinical protocol was approved by our internal
institution’s ethical committee. At inclusion in the study, all
patients discontinued the previous androgen deprivation
therapy and started oral ethinylestradiol at the daily dose of
1 mg. Aspirin (100 mg/daily) was concomitantly given to all
patients at the exception of those who were already using war-
farin for anticoagulation for other indications (18 cases).
Follow up and study end-points
Four patients with a lack of follow-up information were
excluded from the analysis (Fig. 1). The remaining 112 patients
were followed during ethinylestradiol treatment at approxi-
mately 60 days of intervals, including medical history, physical
examination, hematological and biochemical variables
and ECOG score assessment. Imaging was carried out at
6-month intervals or when clinically indicated (biochemical
progression).
The primary end-points were time to PSA progression
and PSA response rate. According to the PSA Working Group
Criteria, a PSA response was defined as a 50% or greater
decrease in serum PSA confirmed by two separate measure-
ments at least 4 weeks apart.1 PSA progression during therapy
was defined as an increase of at least 50% above the nadir
with an absolute increase of 5 ng/mL, or a PSA increase over
25% from the nadir or from baseline for those not meeting the
PSA decline criteria.1 After progression of the disease,
patients were treated at the discretion of the physician (mainly
using chemotherapy).
The secondary end-point was overall survival. Survival time
was measured from baseline to date of death. Other end-points
were represented by the toxicity rate, and need of estrogen
therapy cessation, imaging progression in terms of number and
sites of metastases.
Statistical analysis
Descriptive statistics (SPSS Statistics 19 system [SPSS,
Chicago, IL, USA]) are reported as number and percentage of
cases, mean ± SD, median and range. The relationship between
possible predictive factors and survival was analyzed using
univariate and multivariate logistic regression models (HR and
95% CI).
Kaplan–Meier survival curves were used to evaluate the
median time for PSA progression and overall survival. Patients
with no record of death or progression up to the end of the study
CRPC diagnosis 2000-2010
(n = 158)
Ethinylestradiol therapy
(n = 116)
Alive at last
follow-up
(n = 23)
PC progression
(n = 25)
Toxicity
(n = 0)
Other causes
(n = 3)
Dead during
ethinylestradiol
(n = 28)
Switch to chemotherapy
at progression
(n = 45)
Treatment cessation
for toxicity
(n = 26)
Follow
-up
(4 cases lost)
Included at baseline
(n = 116)
Excluded (did not meet criteria)
(n = 42)
Fig. 1 Flow diagram of the study.
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were censored at their last date of follow up. A 5% level of
significance was used for all statistical testing.
Results
Baseline characteristics
The present study was based on a population of 112 patients.
All patients had a histologically confirmed diagnosis of prostate
adenocarcinoma; patients’ characteristics at baseline and histo-
logical grading are shown in Table 1. In particular, the median
age was 70 years, median PSA was 65.8 ng/mL and median
time of androgen deprivation therapy to start ethinylestradiol
was 4 years. All cases received at least two previous hormone
treatments, and all had confirmed testosterone levels <50 ng/dL
or 1.7 nmol/L. All patients had documented bone metastases.
Survival end-point
The median ethinylestradiol therapy duration was 15.9 months
(range 8–36 months), whereas the median follow up of patients
was 28 months (range 13–36 months). All cases were observed
for at least 12 months. A total of 23 patients (20.5%) were alive
continuing ethinylestradiol therapy at the last follow up.
Overall, 89 patients (79.5%) died during the follow up (28 cases
[25.0%] died during ethinylestradiol therapy, whereas 61
(54.5%) died during the following chemotherapy regimens
(Table 2). The number of deaths during ethinylestradiol therapy
as a result of PC progression, treatment toxicity or other causes
is shown in Table 2.
Median overall survival during ethinylestradiol therapy was
19.52 months (95% CI 18.53–21.47 months) and Kaplan–
Meier curves are shown in Figure 2a.
PSA response and progression
During ethinylestradiol therapy, an initial and confirmed PSA
response was found in 79 patients (70.5%). PSA levels lower
than 4 ng/mL were found in 24 patients (21.4%; Table 2).
PSA progression during therapy was reported in 63 patients
(56.2%). The median time to PSA progression was 15.10
months (95% C I 13.24–18.76 months). The proportion of
patients without PSA progression at 12 months and 24 months
of therapy was 64.3% (72 patients) and 7.1% (8 patients)
respectively. Kaplan–Meier curves for time to PSA progression
are shown in Figure 2b.
During ethinylestradiol therapy, a clinical progression in
terms of new sites of distant metastases (imaging definition)
was found in 44 patients (39.3%), and the median time to
clinical progression was 16.50 months (95% CI 14.48–19.65
months; Table 2).
At progression, 45 of 63 patients discontinued ethiny-
lestradiol, and all started chemotherapy regimens.
Performance status
A total of 68 patients (60.7%) had at baseline an ECOG score
higher than 0. During ethinylestradiol therapy, at PSA response,
48.1%, 51.9% and 0% of patients had an improvement, a sta-
bilization and a deterioration of this parameter, respectively
(Table 2).
Table 1 Patients’ characteristics at baseline
Patient characteristics
No. patients 112
Age (years) 69.9 ± 3.8 (70) 60–77
PSA at baseline (ng/mL) 65.6 ± 30.1 (65.8) 20.1–150.7
Hemoglobin (>11 g/dL) 102 (91.1%)
Elevated alkaline phosphatase
(>130 IU/L)
34 (30.3%)
ECOG score
0 44 (39.3%)
1 45 (40.2%)
2 23 (20.5%)
Previous radical prostatectomy 41 (36.6%)
Previous radiotherapy 66 (58.9%)
Initial androgen deprivation therapy
1. LHRH agonist; 2. at progression
combination with pure
anti-androgen (bicalutamide
50 mg/daily in 47 cases and
flutamide 750 mg/daily in 15 cases)
62 (55.4%)
1. LHRH agonist + pure anti-androgen
(bicalutamide 50 mg/daily in 42
cases and flutamide 750 mg/daily in
8 cases); 2. at progression
anti-androgen withdrawal
50 (44.6%)
Duration of androgen deprivation
therapy (years)
4.5 ± 2.3 (4.0); 2.0–6.5
Gleason score
≤7 (3 + 4) 44 (39.3%)
≥7 (4 + 3) 68 (60.7%)
Bone metastases
1 site 25 (22.3%)
2 sites 54 (48.2%)
>2 sites 33 (29.5%)
Lymph node metastases 36 (32.1%)
Visceral metastases 4 (3.6%)
Values are expressed as n (%) or mean ± SD (median); range.
Table 2 Outcomes during ethinylestradiol therapy
No. patients 112
Alive at the last follow up 23 (20.5%)
Died during ethinylestradiol therapy 28 (25.0%)
PC progression deaths 25 (22.3%)
Cardiovascular toxicity deaths 0 (0)
Other causes 3 (2.7%)
PSA response 79 (70.5%)
PSA <4 ng/mL 24 (21.4%)
No PSA progression at 12 months 72 (64.3%)
No PSA progression at 24 months 8 (7.1%)
Clinical progression (imaging evidence) 44 (39.3%)
Median Time to clinical progression (months) 16.50 (95% CI 14.48–19.65)
ECOG score at PSA response (79 cases)
Improvement 38 (48.1%)
Stabilization 41 (51.9%)
Deterioration 0 (0)
Other treatments after ethinylestradiol
progression (45 cases) or treatment
cessation for toxicity (16)
Docetaxel + prednisone 13
Docetaxel + prednisone + zoledronic acid 48
Values are expressed as n (%) or mean ± SD (median); range.
Ethinylestradiol in CRPC
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Toxicity
Side-effects and toxicity related to ethinylestradiol treatment
are described in Table 3.
A toxicity that required treatment cessation was described in
26 patients (23.2%) at a median time of 16 months. In no
patient was a dose reduction applied.
The main severe toxicity requiring treatment cessation was
thromboembolism (18 patients). No patient died as a result of
treatment toxicity.
Predictors of PSA response
At univariate analysis, tumor Gleason score, duration of previ-
ous androgen deprivation therapies, presence of lymph node
metastases and number of bone metastases were significant
(P < 0.05) predictors of PSA response during therapy. Multi-
variate analysis using the Cox model (Table 4) showed that
tumor Gleason score, duration of previous androgen depriva-
tion therapies and concomitant presence of lymph nodes metas-
tases were significant predictors of PSA response during
ethinylestradiol treatment. In particular, patients with an
absence of lymph nodes progression, more than 4 years of
previous androgen deprivation therapy and a Gleason score ≤7
(3 + 4) were more likely to have a PSA response. Similarly, the
same parameters were significantly associated to overall sur-
vival (Table 4).
Discussion
In the present 10-year experience of metastatic CRPC cases,
estrogen therapy using ethinylestradiol showed to have a clini-
cal therapeutic effect, either in terms of PSA response or as
survival.
Our population was represented by mCRPC patients, all with
bone metastases and an ECOG score ≤2. All patients pro-
gressed after at least two steps of androgen deprivation therapy.
The concept of PSA progression or PSA response was evalu-
ated following guideline indications.1
The oral administration of ethinylestradiol monotherapy was
associated with a very high PSA response rate (70.5%) and a
high percentage (21.4%) of patients with an initial “normaliza-
tion” (<4 ng/mL) of PSA levels. Therefore, the present study
sustains that a high percentage of CRPC patients initially
respond to ethinylestradiol therapy.
The second point is the duration of this positive response. We
found that the proportion of mCRPC cases without a PSA
progression at 12 and 24 months was 64.3% and 7.1%, respec-
tively, and the median time for PSA progression was 15 months.
Considering the oncological characteristics of our population
(CRPC metastatic patients), ethinylestradiol was able to
produce a significant time in which patients were free from PC
progression. The results in terms of survival sustain these data.
The response to ethinylestradiol therapy was also associated
with an improvement (48.1%) or stabilization (51.9%) in the
performance status of the patients.
The rationale for a positive oncological response in CRPC
using estrogen therapy is based to different possible mecha-
nisms of action: (i) a new way of achieving castration in cases
resistant to LHRH agonist activity; (ii) a direct cytotoxic effect
on PC cells; (iii) hyperexpression of estrogen receptors in PC
that can be upregulated by previous androgen deprivation thera-
pies;9 and (iv) effect on sex hormone-binding globulin and free
testosterone.10
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The primary hormonal effect of estrogens is through a feed-
back inhibition of the hypothalamic–pituitary–testicular axis.
Furthermore, estrogens administration has been associated
with a significant decrease in adrenal androgens, such as
dehydroepiandrosterone and dehydroepiandrosterone sulphate
synthesis.11,12 A direct cytotoxic effect on PC cells is sustained
by evidence on castrate xenograph models in vivo5 and PC
cell lines.4
Recently, there has been a renewed interest in using
estrogens. In contrast, it is also true that the development of new
significant treatment strategies for CRPC limits the use of an
old therapy, such as estrogens.
DES is probably the most commonly used estrogen in PC.7,13
However, other estrogen or anti-estrogen therapies have been
recently analyzed in clinical trials including ethinylestradiol14–16
or fulvestrant.17,18 In our opinion, at present there is no real
reason or rationale to prefer one form of estrogen therapy over
the others. We started our experience with ethinylestradiol and
homogeneously continued it for 10 years. No direct comparison
of the activity of the different estrogen therapies or on the
different routes of administration (parenteral, oral, transdermal)
has been carried out. Similarly, differences in the selection of
the populations and in treatment regimens limit the possibility
to compare the present results with those obtained in previous
experiences with estrogen treatments.
In particular, a recent long-term experience with estrogens in
CRPC was reported in the study of Wilkins et al. of 231 CRPC
patients treated with DES.7 The authors described a PSA
response in 30% of cases, a median time for PSA progression of
4.6 months and a median overall survival of 9.3 months. The
population treated with DES by Wilkins et al. included either
metastatic (80%) or non-metastatic (20%) cases.7
A phase 3 trial compared dexamethasone and immediate
DES with dexamethasone and deferred DES in 270 CRPC
patients.13 In the group treated with immediate DES, a PSA
response was achieved in 68% of patients, median time to PSA
progression was 8.6 months and median overall survival was
19.4 months.
On the basis of the results of the clinical trials published in
the literature, EAU 2013 guidelines concluded that DES (as
estrogen therapy) can be an effective form of therapy; however,
there is still concern about the significant cardiovascular
side-effects.1 At present, fewer data are available regarding
ethinylestradiol use, but the present study can represent a
significant experience with positive oncological results in meta-
static CRPC. In a previous experience, Izumi et al. adminis-
tered ethinylestradiol 1.5 mg/daily in a limited number24 of
patients with a CRPC.15 The proportion of cases achieving a
PSA response was 70%, and the median time to PSA progres-
sion was 300 days.
Toxicity related to estrogen treatments is probably the main
problem to be more commonly re-admitted into clinical prac-
tice. As underlined by the EAU guidelines, DES is associated to
a high cardiovascular and thromboembolic toxicity, also reduc-
ing the daily dose.1
Two main strategies have been used to reduce estrogen tox-
icity: a parenteral or transdermal route of administration and
the concomitant use of cardiovascular protective agents.1 The
rate of cardiovascular toxicity in more recent studies was con-
siderably lower than in earlier studies on estrogens where
Table 3 Toxicities
Parameter No. cases No. cases requiring
treatment cessation
Time to treatment
cessation (months)
Gastrointestinal events 74 (66.1%) (all grade 1–2) 0 (0) –
Painful gynecomastia 34 (30.3%) (all grade 1–2) 0 (0) –
Fluid retention 74 (66.1%) (all grade 1–2) 0 (0) –
Cardiac failure 8 (7.1%) (all grade 3) 8 (7.1%) 14 (8–22)
Thromboembolic events 31 (27.7%) (13 cases grade 2 and 18 cases grade 3) 18 (16.1%) 18 (14–22)
Number (%) of events and CTCAE grading; number (%) of cases requiring ethinylestradiol cessation; median (range) time (months) for treatment cessation.
Table 4 Multivariate Cox model for predictors of PSA response and overall survival
Variables PSA response Overall survival
HR P-value HR P-value
Age (years) 0.88 (0.60–1.10) 0.62 0.75 (0.50–1.05) 0.54
PSA at baseline (ng/mL) 1.35 (0.86–2.14) 0.08 1.40 (0.90–2.15) 0.08
Haemoglobin at baseline (g/dL) 0.94 (0.70–1.25) 0.15 1.35 (1.04–1.95) 0.08
Alkaline phosphatase at baseline (IU/L) 0.84 (0.54–1.12) 0.68 0.82 (0.50–1.02) 0.66
Sequence in androgen deprivation treatment 0.42 (0.20–0.95) 0.72 0.48 (0.25–0.98) 0.75
Duration of initial androgen deprivation therapy (months) 1.74 (0.95–2.15) 0.04 1.67 (0.92–2.06) 0.04
Gleason score 1.85 (1.15–2.34) 0.04 2.14 (1.45–3.07) 0.02
Bone metastases (no. sites) 1.13 (0.64–1.85) 0.34 1.18 (0.72–1.94) 0.25
Presence of lymph node metastases at baseline 1.82 (1.20–2.76) 0.04 2.05 (1.54–2.80) 0.02
Previous radical prostatectomy or radiotherapy 0.96 (0.44–1.45) 0.34 0.94 (0.41–1.37) 0.30
HR (95% CI) and P-values.
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anticoagulation was not used routinely.7 In the present study, a
selection of patients on the basis of a history for severe cardio-
vascular diseases has been carried out. Furthermore, aspirin
was concomitantly given to all patients at the exception of those
who were already using other forms of anti-coagulation. In our
experience with ethinylestradiol, thromboembolism remained
the main reason of severe toxicity and treatment cessation, but
with limited rates, and in particular after long periods of treat-
ment (16.1% of patients at a median of 18 months). Also, in the
recent study by Wilkins et al., a concomitant anticoagulation
with aspirin was used and the rate of thromboembolism was
limited to 10% (4.8% required cessation of DES).7 Considered
together, cardiovascular side-effects requiring treatment cessa-
tion were reported in 23% of our patients; this remains a sig-
nificant rate to be considered in the treatment choice.
In the present 10-year experience of metastatic CRPC cases,
the use of ethinylestradiol showed a high percentage of PSA
response. Possible cardiovascular toxicity can be managed
through an accurate patient selection and follow up, and a
concomitant anticoagulation therapy.
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